Its mechanism of action doesn't depend on thyroid function at all, which means it can produce substantial weight loss even when the thyroid is compromised
NICE Technology Appraisal TA875 (2023) recommends semaglutide 2.4 mg (Wegovy) for use in adults with obesity or overweight with at least one weight-related comorbidity, when used alongside a reduced-calorie diet and increased physical activity
Retrieved from Sun, B., Willard, F.S., Feng, D., Alsina-Fernandez, J., Chen, Q., Vieth, M., Ho, J.D., Showalter, A.D., Stutsman, C., Ding, L., Suter, T.M., Dunbar, J.D., Carpenter, J.W., Mohammed, F.A., Aihara, E., Brown, R.A., Bueno, A.B., Emmerson, P.J., Moyers, J.S., Kobilka, T.S., Coghlan, M.P., Kobilka, B.K., Sloop, K.W
I agree with your comments but this class of drugs must be doing more than slowing digestion
Komaroff, MD, Editor in Chief, Harvard Health Letter
Cada pluma contiene 4 dosis, suficientes para 4 semanas de tratamiento
